Y Transformers' First Gathering: The Real Questions and Real Ambitions on the Minds of Post-'98 AI Founders | Event Recap
Nobody's in a rush to leave.
Nobody's in a rush to leave.
"Native Full Modality": Is It Legit?
Long-term support and companionship for the great enterprises of this era as they grow.
Dual-currency, $600 million.
Focused on developing first-in-class and best-in-class Class 1 innovative drugs with global intellectual property rights, with a focus on oncology and chronic disease therapeutics.
Strength is the price of excellence.
The logic of competition isn't "devouring," but "running toward each other."
Focused on R&D of novel drugs for kidney diseases, pan-anemia conditions, and cancer.
Successfully completed the full-system ground test of the space bus IH-1 in the first half of the year.
The Appeal of an All-Gen Z Founding Team